TWI595883B - 用木糖醇穩定化之依那西普調配物 - Google Patents

用木糖醇穩定化之依那西普調配物 Download PDF

Info

Publication number
TWI595883B
TWI595883B TW101138567A TW101138567A TWI595883B TW I595883 B TWI595883 B TW I595883B TW 101138567 A TW101138567 A TW 101138567A TW 101138567 A TW101138567 A TW 101138567A TW I595883 B TWI595883 B TW I595883B
Authority
TW
Taiwan
Prior art keywords
weight
composition
etanercept
peak
hic
Prior art date
Application number
TW101138567A
Other languages
English (en)
Chinese (zh)
Other versions
TW201325611A (zh
Inventor
馬克 曼寧
布萊恩 墨菲
Original Assignee
柯赫勒斯生物科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 柯赫勒斯生物科學有限公司 filed Critical 柯赫勒斯生物科學有限公司
Publication of TW201325611A publication Critical patent/TW201325611A/zh
Application granted granted Critical
Publication of TWI595883B publication Critical patent/TWI595883B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
TW101138567A 2011-10-18 2012-10-18 用木糖醇穩定化之依那西普調配物 TWI595883B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09

Publications (2)

Publication Number Publication Date
TW201325611A TW201325611A (zh) 2013-07-01
TWI595883B true TWI595883B (zh) 2017-08-21

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
TW101138567A TWI595883B (zh) 2011-10-18 2012-10-18 用木糖醇穩定化之依那西普調配物
TW101138565A TWI644681B (zh) 2011-10-18 2012-10-18 用金屬離子穩定化之依那西普調配物
TW101138561A TW201325607A (zh) 2011-10-18 2012-10-18 用胺基酸穩定化之依那西普調配物
TW101138564A TW201325608A (zh) 2011-10-18 2012-10-18 用糖及多元醇之組合穩定化之依那西普調配物
TW101138560A TW201325606A (zh) 2011-10-18 2012-10-18 用氯化鈉穩定化之依那西普調配物
TW101138566A TWI619504B (zh) 2011-10-18 2012-10-18 用美洛明穩定化之依那西普調配物

Family Applications After (5)

Application Number Title Priority Date Filing Date
TW101138565A TWI644681B (zh) 2011-10-18 2012-10-18 用金屬離子穩定化之依那西普調配物
TW101138561A TW201325607A (zh) 2011-10-18 2012-10-18 用胺基酸穩定化之依那西普調配物
TW101138564A TW201325608A (zh) 2011-10-18 2012-10-18 用糖及多元醇之組合穩定化之依那西普調配物
TW101138560A TW201325606A (zh) 2011-10-18 2012-10-18 用氯化鈉穩定化之依那西普調配物
TW101138566A TWI619504B (zh) 2011-10-18 2012-10-18 用美洛明穩定化之依那西普調配物

Country Status (28)

Country Link
US (21) US9801942B2 (enExample)
EP (6) EP2768532A4 (enExample)
JP (6) JP6220788B2 (enExample)
KR (7) KR20140091706A (enExample)
CN (6) CN103998061A (enExample)
AR (6) AR088379A1 (enExample)
AU (6) AU2012326082B2 (enExample)
BR (6) BR112014009131A8 (enExample)
CA (6) CA2851651A1 (enExample)
CY (1) CY1121843T1 (enExample)
DK (1) DK2768525T3 (enExample)
EA (6) EA028520B1 (enExample)
ES (1) ES2734070T3 (enExample)
HK (3) HK1200718A1 (enExample)
HR (1) HRP20191215T1 (enExample)
HU (1) HUE045624T2 (enExample)
IL (6) IL231825A0 (enExample)
IN (3) IN2014CN02527A (enExample)
LT (1) LT2768525T (enExample)
MX (7) MX2014004734A (enExample)
PL (1) PL2768525T3 (enExample)
PT (1) PT2768525T (enExample)
RS (1) RS59179B1 (enExample)
SG (6) SG11201401519RA (enExample)
SI (1) SI2768525T1 (enExample)
SM (1) SMT201900422T1 (enExample)
TW (6) TWI595883B (enExample)
WO (6) WO2013059406A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
IN2014CN02527A (enExample) 2011-10-18 2015-06-26 Coherus Biosciences Inc
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
MX2015015051A (es) * 2013-05-02 2016-06-10 Mabxience S A Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
CN113350278B (zh) * 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
AU2014354384B2 (en) * 2013-11-29 2018-11-08 Ares Trading S.A. A liquid formulation of a fusion protein comprising TNFR and Fc region
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
BR112017013269A2 (pt) 2014-12-22 2018-02-27 Ares Trading S.A. ?composição farmacêutica líquida?
WO2016103034A1 (en) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Protein compositions and use thereof
JP6793996B2 (ja) * 2014-12-31 2020-12-02 エルジー・ケム・リミテッド 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
US20220071901A1 (en) * 2017-11-30 2022-03-10 Bio-Thera Solutions, Ltd. A liquid formulation of humanized antibody for treating il-6-mediated diseases
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20220122993A (ko) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 바이오폴리머 제형을 위한 부형제 화합물
WO2022175663A1 (en) 2021-02-17 2022-08-25 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244805A (zh) * 1996-11-19 2000-02-16 罗赫诊断器材股份有限公司 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US20100158908A1 (en) * 2006-10-20 2010-06-24 Amgen Inc. Stable Polypeptide Formulations

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
CA2444480C (en) * 2001-02-23 2014-05-27 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
EP1603596B1 (en) 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
EP1654281A1 (en) 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
RS54573B1 (sr) 2003-10-14 2016-06-30 F. Hoffmann-La Roche Ltd Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
KR101050585B1 (ko) 2004-03-05 2011-07-19 디에스엠 아이피 어셋츠 비.브이. 연속식 살포 및 교호 접선 흐름에 의한 세포 배양 방법
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
EA014232B1 (ru) 2005-12-20 2010-10-29 Бристол-Маерс Сквибб Компани Стабильные белковые препараты
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US20100016677A1 (en) 2006-03-21 2010-01-21 Eugen Oetringer Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN101627117B (zh) * 2006-08-01 2013-10-30 奇尼塔二有限责任公司 医药制造方法
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US20080311119A1 (en) 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
NZ585702A (en) 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
AU2009204863B2 (en) * 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
EP2260054B1 (en) 2008-02-29 2015-06-03 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
MX2012012526A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo celular mejorado.
RU2600847C2 (ru) 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
WO2012030217A2 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
SG189872A1 (en) 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR20140054002A (ko) 2011-06-29 2014-05-08 인사이트 비젼 인코포레이티드 재발성 눈꺼풀판샘 장애를 치료하는 방법 및 이로 인해 재발 빈도를 감소시키는 방법
IL315908A (en) 2011-07-01 2024-11-01 Amgen Inc Mammalian cell culture
CA2840711C (en) 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
CA2840951A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Methods for purifying fc-fusion protein
US9279014B2 (en) 2011-08-17 2016-03-08 Ares Trading S.A. Methods for preparing an active TNFR-Fc fusion protein
IN2014CN02527A (enExample) * 2011-10-18 2015-06-26 Coherus Biosciences Inc
CA2882551A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244805A (zh) * 1996-11-19 2000-02-16 罗赫诊断器材股份有限公司 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US20070243185A1 (en) * 2002-02-27 2007-10-18 Immunex Corporation Polypeptide formulation
US20100158908A1 (en) * 2006-10-20 2010-06-24 Amgen Inc. Stable Polypeptide Formulations

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954294B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954293B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954295B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US11001627B2 (en) 2012-09-11 2021-05-11 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
EA025267B1 (ru) 2016-12-30
US20190290767A1 (en) 2019-09-26
CN104010654B (zh) 2017-10-27
US20190216930A1 (en) 2019-07-18
LT2768525T (lt) 2019-09-25
US9770510B2 (en) 2017-09-26
KR102068462B1 (ko) 2020-01-22
AR088382A1 (es) 2014-05-28
EA201490802A1 (ru) 2014-08-29
US20130108632A1 (en) 2013-05-02
HK1200718A1 (en) 2015-08-14
IN2014CN02591A (enExample) 2015-06-26
AU2012326171B2 (en) 2017-03-09
WO2013059407A1 (en) 2013-04-25
BR112014009087A2 (pt) 2017-04-18
AU2012326168A1 (en) 2014-04-24
US10980885B2 (en) 2021-04-20
US20180193463A1 (en) 2018-07-12
CN104010658A (zh) 2014-08-27
EA026410B1 (ru) 2017-04-28
TW201325610A (zh) 2013-07-01
EP2768535A1 (en) 2014-08-27
JP6110393B2 (ja) 2017-04-05
JP6113176B2 (ja) 2017-04-12
US20200405865A1 (en) 2020-12-31
HK1200851A1 (en) 2015-08-14
HK1200722A1 (en) 2015-08-14
IL231827A0 (en) 2014-05-28
EP2768531A4 (en) 2015-03-11
KR20140079491A (ko) 2014-06-26
US11135267B2 (en) 2021-10-05
BR112014009131A8 (pt) 2017-06-20
BR112014009031A2 (pt) 2017-05-09
AU2012326082A1 (en) 2014-04-24
KR20140097184A (ko) 2014-08-06
CN103998061A (zh) 2014-08-20
US9302002B2 (en) 2016-04-05
AR088383A1 (es) 2014-05-28
EA201490817A1 (ru) 2014-09-30
KR20200008021A (ko) 2020-01-22
US10772963B2 (en) 2020-09-15
EP2768525B1 (en) 2019-06-19
AU2012326170A1 (en) 2014-04-24
US20180125982A1 (en) 2018-05-10
AU2012326084B2 (en) 2016-12-15
AR088379A1 (es) 2014-05-28
US20190314498A1 (en) 2019-10-17
US20130108633A1 (en) 2013-05-02
JP2014530254A (ja) 2014-11-17
JP2014530864A (ja) 2014-11-20
AR088380A1 (es) 2014-05-28
AU2012326170B2 (en) 2016-12-22
CN104011073B (zh) 2017-08-25
MX2019009176A (es) 2019-10-07
CN103998060A (zh) 2014-08-20
CA2851642A1 (en) 2013-04-25
US20190290765A1 (en) 2019-09-26
EP2768854A4 (en) 2015-03-11
US10888619B2 (en) 2021-01-12
EP2768533A1 (en) 2014-08-27
JP2014530863A (ja) 2014-11-20
IN2014CN02527A (enExample) 2015-06-26
SG11201401576WA (en) 2014-10-30
SI2768525T1 (sl) 2019-10-30
JP2014530862A (ja) 2014-11-20
US10980884B2 (en) 2021-04-20
BR112014009146A8 (pt) 2017-06-20
WO2013059412A1 (en) 2013-04-25
AU2012326080A1 (en) 2014-04-24
MX367054B (es) 2019-08-02
US9943601B2 (en) 2018-04-17
JP2014530256A (ja) 2014-11-17
CA2851635A1 (en) 2013-04-25
US9801942B2 (en) 2017-10-31
US10213508B2 (en) 2019-02-26
AR088460A1 (es) 2014-06-11
TW201325606A (zh) 2013-07-01
CA2851651A1 (en) 2013-04-25
ES2734070T3 (es) 2019-12-04
RS59179B1 (sr) 2019-10-31
CN104011073A (zh) 2014-08-27
MX2014004726A (es) 2015-05-15
DK2768525T3 (da) 2019-07-22
US10987405B2 (en) 2021-04-27
EP2768532A4 (en) 2015-03-11
KR20140083037A (ko) 2014-07-03
US20190184017A1 (en) 2019-06-20
IN2014CN02592A (enExample) 2015-09-04
HK1200719A1 (en) 2015-08-14
CN103998060B (zh) 2016-12-21
US20190298837A1 (en) 2019-10-03
MX2014004734A (es) 2015-05-15
AU2012326171A1 (en) 2014-04-24
EA027325B1 (ru) 2017-07-31
TWI619504B (zh) 2018-04-01
KR20140091705A (ko) 2014-07-22
EP2768854A1 (en) 2014-08-27
PL2768525T3 (pl) 2019-10-31
US20160199489A1 (en) 2016-07-14
JP6220788B2 (ja) 2017-10-25
SMT201900422T1 (it) 2019-09-09
CA2851628A1 (en) 2013-04-25
BR112014009073A2 (pt) 2017-05-09
JP6199298B2 (ja) 2017-09-20
US20190290766A1 (en) 2019-09-26
AU2012326080B2 (en) 2017-02-16
CN104010654A (zh) 2014-08-27
WO2013059408A1 (en) 2013-04-25
US20160317667A1 (en) 2016-11-03
BR112014009146A2 (pt) 2017-06-13
CY1121843T1 (el) 2020-07-31
EP2768532A1 (en) 2014-08-27
EP2768531A1 (en) 2014-08-27
IL231825A0 (en) 2014-05-28
EA201490815A1 (ru) 2014-09-30
WO2013059406A1 (en) 2013-04-25
IL231824A0 (en) 2014-05-28
HRP20191215T1 (hr) 2019-10-04
CA2851646A1 (en) 2013-04-25
MX2014004725A (es) 2015-02-05
MX2014004733A (es) 2015-05-15
MX2014004728A (es) 2015-05-15
IL231828A0 (en) 2014-05-28
TW201325611A (zh) 2013-07-01
US11129876B2 (en) 2021-09-28
CA2851639C (en) 2020-12-29
JP6220789B2 (ja) 2017-10-25
EA028520B1 (ru) 2017-11-30
JP6104922B2 (ja) 2017-03-29
AR088381A1 (es) 2014-05-28
SG11201401563SA (en) 2014-09-26
TW201325607A (zh) 2013-07-01
TW201325608A (zh) 2013-07-01
SG11201401562RA (en) 2014-09-26
MX2014004732A (es) 2015-05-15
US20190290768A1 (en) 2019-09-26
IL231826A0 (en) 2014-05-28
BR112014009022A2 (pt) 2017-05-02
US20130101640A1 (en) 2013-04-25
JP2014530255A (ja) 2014-11-17
SG11201401517VA (en) 2014-09-26
EP2768535A4 (en) 2015-03-11
US20130101584A1 (en) 2013-04-25
US20190314499A1 (en) 2019-10-17
SG11201401567YA (en) 2014-07-30
AU2012326084A1 (en) 2014-04-17
US20190314500A1 (en) 2019-10-17
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
US10376588B2 (en) 2019-08-13
EA201490804A1 (ru) 2014-09-30
HK1200720A1 (en) 2015-08-14
EP2768533A4 (en) 2015-03-11
IL231829A0 (en) 2014-05-28
KR102163150B1 (ko) 2020-10-08
EP2768525A1 (en) 2014-08-27
CA2851639A1 (en) 2013-04-25
EA025663B1 (ru) 2017-01-30
EA201490803A1 (ru) 2014-09-30
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
BR112014009131A2 (pt) 2017-06-13
AU2012326082B2 (en) 2016-12-15
KR20140091707A (ko) 2014-07-22
TW201325609A (zh) 2013-07-01
CN104010657A (zh) 2014-08-27
PT2768525T (pt) 2019-07-17
KR20140091706A (ko) 2014-07-22
AU2012326168B2 (en) 2016-12-15
HUE045624T2 (hu) 2020-01-28
HK1200721A1 (en) 2015-08-14
EA201490801A1 (ru) 2014-09-30
EP2768525A4 (en) 2015-07-15
TWI644681B (zh) 2018-12-21
SG11201401519RA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
TWI595883B (zh) 用木糖醇穩定化之依那西普調配物
US11000588B2 (en) Etanercept formulations stabilized with sodium chloride

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees